Hetero Launches India's First Generic Of Gilead’s Biktarvy
Introduces Combination Product Under Voluntary License
Executive Summary
Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product. Gilead is entitled to a “modest royalty” on products produced under the voluntary license.
You may also be interested in...
Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance
HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.
Gilead Keeps Close Eye On Stormy Remdesivir Situation In India
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.
Pharma Execs Jumping Onboard Private Equity Train
More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.